Comparing the Effects of Levobupivacaine and Bupivacaine in Saddle Spinal Anesthesia
Outpatients, General Surgery, Anorectal Disorder
About this trial
This is an interventional other trial for Outpatients focused on measuring Saddle block, Hyperbaric levobupivacaine and bupivacaine, Outpatient anorectal surgery
Eligibility Criteria
Inclusion Criteria:
- ASA I-II risk group with planned elective anorectal surgery
- Approved to participate in the study and spinal anesthesia
Exclusion Criteria:
- Known hypersensitivity to amid-type local anesthetics
- Not to accept regional anesthesia administration
- With preoperative motor and sensory loss
- Not to accept participation in the study
- Contraindications for spinal anesthesia method
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Group L (Hyperbaric Levobupivacaine)
Group B (Hyperbaric Bupivacaine)
7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. In order to obtain hyperbaric levobupivacaine, 1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) was added to 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water.
7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (Marcaine® Spinal Heavy, 0.5%, 4 mL ampoule, AstraZeneca/England, Eczacıbaşı/Turkey, dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds.